Wyeth Reports Earnings Results for the 2007 Third Quarter and First N...(the Company's Board ofDirectors approved...),Health

Date:10/18/2007

the Company's Board of Directors approved an increase to the Company's previously authorized share repurchase program, which inclusive of approximately $1.2 billion in repurchases already executed in 2007, authorizes the Company to buy back up to $5.0 billion of the Company's common stock. The repurchase program has no time limit and may be suspended for periods or discontinued at any time. The Company intends to fund the share repurchase program with cash from operations.

Increase in Common Stock Dividend

As previously announced, on September 27, 2007, the Company declared a dividend of twenty-eight cents ($0.28) per share on the outstanding shares of its common stock, payable on December 3, 2007 to stockholders of record at the close of business on November 13, 2007. This quarterly rate represents a 7.7% increase per share from the previous quarter ($0.26).

Segment Information

The following table sets forth worldwide net revenue by reportable segment together with the percentage changes from the comparable period in the prior year:

(UNAUDITED)

Three Months Ended Nine Months Ended

9/30/2007 9/30/2007

Net Revenue By

Reportable Segment ($ in millions) Increase ($ in millions) Increase

Pharmaceuticals $4,670 10% $13,898 10%

Consumer Healthcare 715 8% 1,949 7%

Animal Health 235 11% 789 8%

Consolidated Total $5,620 9% $16,636 10%

Pharmaceuticals

Worldwide Pharmaceuticals net revenue increased 10% for the 2007 third quarter and first nine months due primarily to higher sales of Effexor, Prevnar, Enbrel, Nutrition products and Zosyn(R). Protonix(R) sales decreased 6% for the 2007 third quarter, reflecting
'/>"/>

SOURCE Wyeth Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13
Related medicine news :

1. Wyeth Launches Vaccine for Pneumococcal Disease in India
2. Wyeth Embroiled in a Lawsuit over its Hormone Replacement Therapy
3. Wyeth Pharma Wins Law Suit
4. Verdict Against Wyeth Pharma in Prempro Case
5. FDA Approves Wyeths Oral Contraceptive Lybrel
6. Autopsy reports could be valuable and informative
7. China reports declining number of SARS Cases
8. Russia Reports First SARS Case
9. Research reports that c-section deliveries are rising
10. Jharkhand reports 13,000 Malaria cases
11. Uganda Reports Failure To Contain Sleeping Sickness